For Dr. Aller, precision medicine is about more than genomic tools, it’s about ensuring that the strongest clinical evidence meaningfully improves patient care. Her work focuses on bridging the gap between landmark clinical trials and the real-world decisions clinicians and patients face every day.
In a recent study examining breast cancer care in the post-TAILORx era, Dr. Aller and colleagues explored how genomic testing is being integrated into routine practice and how it influences treatment decisions across patient populations. The research reflects her ongoing commitment to understanding not only whether evidence changes guidelines, but how it is applied in real clinical settings.
By studying patterns of genomic testing and treatment decisions, Dr. Aller aims to ensure that precision oncology is used thoughtfully, equitably, and in ways that truly benefit patients. Her work highlights the importance of continuously evaluating how personalized cancer care is delivered and identifying opportunities to improve decision-making for all patients.
Aller A, Zhu S, Lyon L, et al. Is age just a number? Oncotype DX testing and chemotherapy use in the post-TAILORx era. Cancer. 15 Dec 2025; 131(24): e70218. DOI: 10.1002/cncr.70218